The immediate precursor to NAD+ in the salvage pathway: NMNAT enzymes convert it to NAD+ in a single step. Whether NMN enters cells intact is genuinely disputed — a dedicated transporter (Slc12a8) has been reported, but the prevailing view is that most NMN is dephosphorylated to nicotinamide riboside at the cell surface, taken up, and re-phosphorylated. The distinction matters commercially far more than it does biologically.
Human trials consistently show NMN raises blood NAD+ levels. Effects on outcomes that matter — insulin sensitivity, muscle function, ageing markers — have been modest, inconsistent, and typically from small studies. The gap between the biomarker and the benefit is the whole story of this field.
Not an FDA-approved drug. Its supplement status is genuinely unsettled: FDA has concluded NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug and substantial clinical investigations were instituted and made public. That position is contested by industry and litigation has followed.
Well tolerated in trials up to the doses studied, over relatively short durations. Long-term human data do not exist. The same theoretical oncological consideration applies as for NAD+.
Forge Bioenergy does not publish dosing, reconstitution, or administration protocols for any peptide. See our editorial policy for why. If you are considering any substance on this page, that conversation belongs with a licensed physician.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.